Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy

Journal of Clinical Investigation

Volumn 107, Issue 8, 2001, Pages 967-974

  Freeman, K ^a   Lerman, I ^a   Kranias, E G ^a   Bohlmeyer, T ^a   Bristow, M R ^a   Lefkowitz, R J ^a   Iaccarino, G ^a   Koch, W J ^a   Leinwand, L A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PHOSPHOLAMBAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CARDIOMYOPATHY; CONTROLLED STUDY; EXCITATION CONTRACTION COUPLING; GENE EXPRESSION; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE REMODELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0035048223     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI12083     Document Type: Article

References (36)

1. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
2. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial
3. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
4. Beta-adrenergic receptor blockade in chronic heart failure
5. Catecholamines, cardiac beta-adrenergic receptors, and heart failure
6. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy
7. Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice
8. Low- and high-level transgenic expression of beta2-adrenergic receptors differentially affect cardiac hypertrophy and function in Galphaq-over-expressing mice
9. BetaARK1 inhibition improves survival and cardiac function in a mouse model of severe cardiomyopathy
10. Is calcium the 'cure' for dilated cardiomyopathy?
11. Mice expressing mutant myosin heavy chains are a model for familial hypertrophic cardiomyopathy
12. Progression from hypertrophic to dilated cardiomyopathy in mice that express a mutant myosin transgene
13. Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor
14. Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor
15. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation
16. Cardiac troponin T mutations result in allele-specific phenotypes in a mouse model for hypertrophic cardiomyopathy
17. Ablation of the murine alpha myosin heavy chain gene leads to dosage effects and functional deficits in the heart
18. Phospholamban deficiency does not compromise exercise capacity
19. Alpha-skeletal muscle actin mRNA's accumulate in hypertrophied adult rat hearts
20. Pressure- and volume-induced left ventricular hypertrophies are associated with distinct myocyte phenotypes and differential induction of peptide growth factor mRNAs
21. Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: Critical role for expression level
22. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice
23. Cardiomyopathy induced by cardiac Gs alpha overexpression
24. Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis: Role of a pertussis toxin-sensitive G protein
25. Low-dose enoximone improves exercise capacity in chronic heart failure
26. In vivo echocardiographic detection of enhanced left ventricular function in gene-targeted mice with phospholamban deficiency
27. Regulatory effects of phospholamban on cardiac function in intact mice
28. Decoding calcium signals involved in cardiac growth and function
29. Structure and mechanism of the G protein-coupled receptor kinases
30. Expression of beta-arrestins and beta-adrenergic receptor kinases in the failing human heart
31. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes
32. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family
33. Cardiac BARK inhibition improves survival and augments beta blocker therapy in a mouse model of severe heart failure
34. Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade
35. Overexpression of the cardiac beta(2)-adrenergic receptor and expression of a beta-adrenergic receptor kinase-1 (betaARK1) inhibitor both increase myocardial contractility but have differential effects on susceptibility to ischemic injury
36. Phospholamban knock-out (PLB-KO) mice exhibit increased susceptibility to myocardial ischemic injury: A gender-specific effect